LACTEL DL-PL B6014-1 is an acid-terminated poly(DL-lactide) supplied as a biomedical-grade resorbable polyester. The DL-lactide repeat unit is derived from a racemic mixture of D- and L-lactide; the resulting chain architecture is amorphous and lacks the crystalline melting endotherm observed in poly(L-lactide). The polymer dissolves in dichloromethane, chloroform, tetrahydrofuran, and N-methyl-2-pyrrolidone, and is insoluble in water, ethanol, and aliphatic hydrocarbons. The acid-terminated designation indicates that chain ends are predominantly carboxylic acid groups rather than ester-capped moieties; this end-group functionality is intentional for degradation control and for potential conjugation to amine- or hydroxyl-terminated payloads. The B6014-1 designation identifies a specific lot-controlled molecular-weight/viscosity grade within the LACTEL DL-PL series. The raw material is not a finished medical device; it is intended for further processing into injectable microspheres, in situ forming implants, solvent-cast films, and drug-eluting matrices. Final devices must undergo biological evaluation under ISO 10993-1. The manufacturer supplies the polymer under its quality system and provides a certificate of analysis for lot-specific residual monomer, residual solvent, water content, and elemental impurity results.

What Specification Parameters Define the B6014-1 Grade?

The routine release parameter is inherent viscosity, measured in chloroform at 25 °C with a 0.1% w/v solution using an Ubbelohde viscometer according to ISO 1628-1:2022. The acid number is determined by titration in tetrahydrofuran/water and expressed as mg KOH/g; this value differentiates acid-terminated from ester-capped DL-PL because only the former carries measurable free carboxylic acid end groups. Water content is measured by Karl Fischer titration per USP <921> and is controlled because residual moisture drives hydrolysis during melt processing. Residual solvents are analyzed by headspace gas chromatography per USP <467>; residual lactide monomer is determined by gas chromatography with flame ionization detection. Elemental impurities are measured by USP <232>/USP <233>; endotoxin load, where specified, is assessed by limulus amebocyte lysate per USP <85>.

Proton nuclear magnetic resonance spectroscopy in deuterated chloroform verifies the DL-lactide repeat unit; methine and methyl resonances appear near 5.2 ppm and 1.6 ppm, respectively, but end-group quantification is limited by low signal intensity for high-molecular-weight lots. Absolute molecular weight is characterized by size-exclusion chromatography with multi-angle light scattering in tetrahydrofuran; conventional calibration against polystyrene standards is not absolute for PLAs and can overestimate molar mass because of hydrodynamic volume differences. The combination of acid number and SEC-MALS provides an estimate of number-average molecular weight from end-group concentration and polymer mass. Assuming one carboxylic acid end group per linear chain, number-average molecular weight is estimated as 56,100 divided by acid number in mg KOH/g; deviation from this estimate indicates chain branching, residual free acid, or mixed end groups. Published numerical lot-release limits for B6014-1 are not publicly itemized; residual monomer and residual solvent maxima must be obtained from the certificate of analysis. The manufacturer controls these attributes under an ISO 13485 quality management system.

Solvent-based manufacturing is preferred because amorphous poly(DL-lactide) softens above its glass transition, typically in the 50–60 °C range for dry samples by differential scanning calorimetry per ISO 11357-2. For microsphere preparation, the polymer is dissolved in dichloromethane at 5–15% w/v and introduced into an aqueous continuous phase through a rotor-stator homogenizer or in-line static mixer. Solvent extraction is conducted at 2–8 °C to limit premature particle collapse and to control internal porosity. For melt processing, a conical twin-screw micro-compounder with L/D 25:1 and barrel temperatures of 140–180 °C is a typical development-scale configuration, but published data for this specific grade in that equipment is limited. The processing window is narrow because temperatures above 200 °C lead to thermal depolymerization and lactide regeneration, while temperatures below 140 °C produce high melt viscosity and incomplete plastication. Pre-drying at 30–40 °C under vacuum to a moisture content below 0.1% is required before melt compounding; residual moisture above 0.2% at melt temperature causes hydrolytic chain scission and measurable inherent-viscosity loss during compounding. Prolonged residence time at elevated temperature should be minimized because polyester degradation is time–temperature dependent; quantitative degradation-rate data for B6014-1 in injection molding are not publicly established.

For electrospinning, solutions of 8–12% w/v in hexafluoroisopropanol or chloroform/dimethylformamide are used; solution conductivity and viscosity are adjusted by solvent ratio rather than by adding ionic salts, because excess ionic additives can complex with carboxylic acid chain ends and alter fiber surface chemistry. For solvent-cast films, a continuous coater with slot-die application and forced-air drying can produce thicknesses from 20–200 µm; residual solvent removal is confirmed by headspace GC before device assembly. Microsphere batches in the 10–100 µm size range are typically collected by filtration or centrifugation and lyophilized; the final residual solvent level should meet USP <467> limits for the intended route of administration.

When Acid-Terminated DL-PL Replaces Ester-Terminated PLA or Poly(L-lactide) in Drug-Eluting Matrices

Several structural differences separate acid-terminated DL-PL from other resorbable PLA and PLGA products. The carboxylic acid chain ends increase local hydrophilicity and accelerate water uptake in the amorphous matrix; in vitro degradation per ASTM F1635-16 in phosphate-buffered saline at 37 °C generally shows faster mass loss for acid-terminated DL-PL than for an ester-capped DL-PL of comparable initial molecular weight. The direction of this effect is consistent with autocatalytic ester hydrolysis in PLAs; published degradation-rate data for the specific B6014-1 lot configuration are limited. The amorphous DL-lactide backbone has no crystalline regions; poly(L-lactide) typically shows a melting endotherm near 170–180 °C and slower hydrolytic degradation because water ingress is restricted in crystalline domains. Compared with 50:50 PLGA, poly(DL-lactide) lacks glycolide repeat units, which reduces hydrolytic rate and acid burst; this shift is relevant when a longer implant residence time or lower initial acid burden is required.

The free carboxylic acid end group allows carbodiimide-mediated coupling to amine-terminated biologic payloads; this is not available to ester-capped DL-PL of the same backbone. The same reactivity imposes incompatibility with nucleophilic additives during melt processing: primary and secondary amines, amine-based stabilizers, alkoxide catalysts, and high-temperature amide solvents should be avoided because they attack the ester backbone and generate oligomeric fragments. If a drug substance is basic or nucleophilic, the acid-terminated grade may form ionic or covalent adducts under melt processing; in such cases, solvent-based encapsulation or solid-state mixing at low temperature is preferred. In vitro release comparisons should be generated under USP Apparatus 2 or 4 with sink conditions and appropriate sampling intervals; without those data, specific drug-loading or release-performance claims are not warranted.

Degradation of poly(DL-lactide) proceeds by bulk hydrolysis of ester bonds. Acid-terminated PLAs show autocatalytic acceleration in thicker implants because carboxyl end groups and generated lactic acid oligomers lower internal pH. In microspheres, the rate of this internal pH drop is a function of particle size, initial molecular weight, and end-group density; the acid-terminated grade shifts the initial pH microclimate lower at equivalent molecular weight. This behavior is exploited for drug release but must be confirmed by in vitro degradation studies according to ASTM F1635-16, with mass loss, molecular weight loss, and pH monitored over time.

Within the LACTEL DL-PL family, the B6014-1 grade is differentiated by its solution-viscosity specification and end-group type rather than by monomer composition. A lower-viscosity DL-PL grade may provide easier solvent dissolution and faster molecular-weight loss, while a higher-viscosity grade may improve mechanical durability but reduce processability in small-diameter fibers. The choice among grades is therefore formulation-specific; comparative evaluation should include melt viscosity or solution viscosity, residual monomer, and ASTM F1635-16 degradation behavior under the intended device geometry.

Material Handling, Sterilization, and Storage Limits

Raw B6014-1 is typically packaged in vacuum-sealed, nitrogen-flushed foil pouches and should be stored at −20 °C in a low-humidity freezer. Exposure to ambient air at relative humidity above 60% should be limited to less than 1 h before use because amorphous poly(DL-lactide) can take up 0.3–0.5% moisture within 24 h at 25 °C. Pre-drying should be performed in a vacuum oven at 30–40 °C for 24–48 h, or in a dry-air hopper with a dew point below −40 °C for melt processing; Karl Fischer titration should confirm moisture below 0.1% before extrusion. For terminal sterilization, ethylene oxide per ISO 11135 is common for moisture-sensitive resorbable polyesters; gamma irradiation and electron beam can cause significant chain scission, so if radiation sterilization is unavoidable, dose mapping and post-irradiation inherent-viscosity measurement are required. Published data for radiation degradation of B6014-1 specifically are limited; general studies on PLA show that molecular weight loss is dose-rate and temperature dependent. Steam sterilization is not appropriate because the material softens near its glass transition and undergoes rapid hydrolytic degradation in saturated steam.

The polymer is incompatible with strong bases, primary and secondary amines, alcohols at elevated temperature due to transesterification, and oxidizing agents. Process contact surfaces should be 316L stainless steel, glass, or PTFE; prolonged contact with copper or iron in acidic solution should be avoided because transition metals can accelerate oxidative degradation. For solvent processing, dichloromethane and chloroform are removed by vacuum drying at 25–35 °C to avoid localized film blistering; residual solvent analysis should be completed before downstream assembly. When the polymer is stored as a solution, solutions should be prepared immediately before use and kept refrigerated at 2–8 °C for no more than 24 h because carboxylic acid end groups catalyze slow backbone hydrolysis in the presence of residual water.

For freeze-drying of microparticle suspensions, the glass transition of the wet formulation may be depressed below −20 °C by residual solvent and water; conservative lyophilization cycles use primary drying at −40 °C and secondary drying at 20–30 °C to prevent particle rupture. The use of trehalose or mannitol as lyoprotectants is common in resorbable particle formulations, but exact excipient ratios require formulation-specific optimization. Drying temperatures above 40 °C should be avoided when amorphous particles are present because sintering can occur near the depressed glass transition.

Because the polymer is used as a raw material in drug-delivery systems, the final manufacturer should obtain lot-specific documentation covering residual ethylene oxide if applicable, residual tin or alternative catalyst content, and storage temperature excursions. The supplier typically provides a certificate of analysis and a certificate of conformance, but compendial testing of the final formulation remains the responsibility of the finished-device manufacturer. The absence of publicly listed numeric lot-release limits for B6014-1 does not imply absence of controls; these limits are maintained in the manufacturer’s quality system and are disclosed under confidentiality agreements for regulatory submissions.

Downstream device manufacturers use the polymer in solvent-cast bioresorbable films with thicknesses from 20–200 µm, in microsphere batches with particle diameters from 10–100 µm, and in extrusion-based rods for orthopedic research. Solvent removal must meet USP <467> or ICH Q3C limits for the intended route of administration; microsphere collapse is controlled by maintaining the continuous phase below the polymer glass transition and by using solvent extraction rather than rapid evaporation. The final device must be tested under ISO 10993-1 for cytotoxicity, sensitization, and irritation, and for longer-term implantation under ISO 10993-6; the raw polymer certificate of analysis does not replace biological evaluation of the finished article. For drug-eluting systems, in vitro release testing under USP Apparatus 4 with infinite sink conditions can be used to compare formulation variants, but in vitro–in vivo correlation should not be assumed without appropriate pharmacokinetic modeling.